➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
McKinsey
Medtronic
Moodys
AstraZeneca

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,957,232

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,957,232 protect, and when does it expire?

Patent 9,957,232 protects STIVARGA and is included in one NDA.

This patent has forty-one patent family members in thirty-seven countries.

Summary for Patent: 9,957,232
Title:4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenox- y]-N-methylpyridine-2-carboxamide monohydrate
Abstract: The present invention relates to 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluoropheno- xy]-N-methylpyridine-2-carboxamide monohydrate, to processes for its preparation, to pharmaceutical compositions comprising it and to its use in the control of disorders.
Inventor(s): Grunenberg; Alfons (Dormagen, DE), Stiehl; Juergen (Sprockhovel, DE), Tenbieg; Katharina (Dortmund, DE), Keil; Birgit (Dusseldorf, DE)
Assignee: BAYER HEALTHCARE LLC (Whippany, NJ)
Application Number:12/444,974
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,957,232
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 9,957,232

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Bayer Hlthcare STIVARGA regorafenib TABLET;ORAL 203085-001 Sep 27, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,957,232

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06021296Oct 11, 2006
PCT Information
PCT FiledSeptember 29, 2007PCT Application Number:PCT/EP2007/008503
PCT Publication Date:April 17, 2008PCT Publication Number: WO2008/043446

International Family Members for US Patent 9,957,232

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 062927   Start Trial
Australia 2007306716   Start Trial
Brazil PI0719828   Start Trial
Canada 2666170   Start Trial
Chile 2007002930   Start Trial
China 101547903   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Moodys
Johnson and Johnson
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.